BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

Search i

Search help

  • Enter one or more search terms in the search field. Upper and lower case are not relevant.
  • As soon as you have entered three letters in the search field, various search words will be suggested from which you can choose one.
  • If you are searching for a certain group of words, put these words in double quotes. The hits will then contain the words in the order you entered, e.g. "medicines for children".
  • Multiple search terms can also be combined with the Boolean operators AND and OR. When using the operator AND, the results contain the intersection of all search terms. When using the operator OR, the hits contain one of the search terms or only individual search terms. The result set is therefore significantly larger. Please note that these operators must be written in capital letters.
  • If you receive a (too) large number of hits as a result of your search, you can narrow it down by using filters. These filter options appear to the left of the search results and are subdivided into:

    • category (e.g. safety of medicinal products, medical devices, code systems)
    • format (e.g. download, risk information, DHPCs)
    • time interval (e.g. last 30 days, older than ...)
  • Selected filters can be removed individually or all at once ("Show all results").
  • By default, search results are sorted by relevance, but they can also be sorted chronologically ("Latest entries first" or "Oldest entries first").

Enter search term

442 results

Results per page: 10 20 30

Dear Doctor Letter (Rote-Hand-Brief) on Revlimid® (lenalidomide): New important information on reactivation of virus infections PDF, 335KB, File is accessible Date: 08. November 2016 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: lenalidomide

The company Celgene GmbH is circulating information that cases of virus reactivation after treatment with lenalidomide have been reported.

Information Letter on acitretin and teratogenicity: Extension of the contraception period and the prohibition of blood donation after end of therapy PDF, 98KB, File is accessible Date: 08. November 2016 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: acitretin

In an Information Letter, the companies Dermapharm and Puren Pharma point out the extension of the contraception period and the prohibition of blood donation up to three years after discontinuation of therapy with acitretin.

Information letter on emergency hormonal contraceptives (e.g. Postinor®): New recommendations for women taking CYP3A4 inducers PDF, 93KB, File does not meet accessibility standards Date: 26. September 2016 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: levonorgestrel

The company Gedeon Richter Pharma GmbH is circulating new recommendations for women taking liver enzyme inducers. Active substances that trigger such an induction include e.g. preparations containing St. John's wort, rifampicin, certain HIV

Dear Doctor Letter (Rote-Hand-Brief) on GlucaGen® HypoKit (glucagon hydrochloride): Batch recall due to quality defect Date: 07. September 2016 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: glucagon hydrochloride

The company Novo Nordisk Pharma GmbH is circulating information that 3 batches of the GlucaGen® HypoKit are being recalled in Germany.

Renewed information on Erwinase® 10,000 IU/vial (crisantaspase): Shortage and instructions for use for further batches 174aG116 and 177aG116 PDF, 303KB, File is accessible Date: 26. August 2016 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: crisantaspase

In connection with the import of Erwinase® from The United Kingdom, the company Jazz Pharmaceuticals Germany GmbH is circulating information on the fact that a 5 μm filter needle is to be used when administering batches 174aG116 and 177aG116.

Dear Doctor Letter (Rote-Hand-Brief) on Zydelig® (Idelalisib): Updated recommendations following conclusion of the safety data evaluation PDF, 600KB, File is accessible Date: 23. August 2016 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: idelalisib

The company Gilead Sciences GmbH is circulating information on the updated indication of idelalisib as first-line treatment of patients with chronic lymphocytic leukaemia (CLL) and on risk minimisation measures for prevention of infections.

Arcoxia® (etoricoxib): Altered dosage recommendations for patients with rheumatoid arthritis and ankylosing spondylitis (Bekhterev's disease) PDF, 902KB, File is accessible Date: 19. July 2016 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: etoricoxib

The company MSD is circulating information on altered dosage recommendations for the medicinal product Arcoxia®.

Dear Doctor Letter (Rote-Hand-Brief) on Noxafil® (posaconazole): Tablets and oral suspension are not interchangeable PDF, 784KB, File is accessible Date: 18. July 2016 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: posaconazole

The company MSD is circulating information on the broad-spectrum antimycotic Noxafil® with regard to the use of different pharmaceutical forms.

Information letter on Etopophos® 100-/1000 mg (etoposide): Shortage and procedure for ordering PDF, 146KB, File is accessible Date: 14. July 2016 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: etoposide

The company Bristol-Myers Squibb GmbH & Co. KGaA is circulating information regarding the shortage of Etopophos® 100-/1000 mg.

Dear Doctor Letter (Rote-Hand-Brief) on Adempas® (riociguat): New contraindication for patients with pulmonary hypertension in connection with idiopathic interstitial pneumonia (PH-IIP) PDF, 900KB, File is accessible Date: 05. July 2016 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: riociguat

In coordination with the European Medicines Agency the companies Bayer and MSD are circulating a Dear Doctor Letter on Adempas® with information regarding preliminary results of the RISE-IIP study.